SecBot SecBot
8-K ·Filed Nov 10, 2026

ACRV

Acrivon Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 8h ago SEC0001193125-26-455669
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for initiation of Phase 2 trials for ACR-525 in EoE and for any partnership or financing updates given the company's $69M market cap and early-stage pipeline.

DirectionNeutral
Confidencemedium
Horizonmonths

ACR-525

● Neutral Named in this 8-K
Impact
Phase
Phase 2-ready (Phase 1 completed)
Time to market
ACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).
Next catalyst
None dated

What to watchWatch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.57
T+0 close · Nov 10, 2026 · via day close
Latest settled
−7.01%
T+1 · $1.46
Vs SPY
−6.65%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $1.57entry
  2. T+1 · 5d ago −7.01%α −6.65% · $1.46
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acrivon Therapeutics hosted a corporate R&D webcast with Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, including the Phase 2-ready oral selective JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program, both identified via its AI-driven AP3 platform. The presentation highlighted preclinical and Phase 1 data for ACR-525, positioning it for initial development in eosinophilic esophagitis (EoE), a large and growing market with significant unmet need for oral therapies.

Key Facts

  • Acrivon introduced ACR-525, a Phase 2-ready oral selective JAK1 inhibitor, for initial development in EoE.
  • ACR-525 is wholly-owned with composition of matter protection through 2038.
  • Phase 1 data showed dose-proportional PK (T1/2 ~12h), safe and tolerable with no SAEs, and dose-dependent CXCL10 decrease.
  • ACR-525 demonstrated high JAK1 selectivity (49x biochemical, >120x cellular vs JAK2) and differentiated pathway effects including TGFβ suppression and no pro-apoptotic BAD activation.
  • A preclinical PKCθ inhibitor program was also presented, with a rationale for combination with ACR-525.
  • EoE prevalence in the US has grown 477% over 13 years to >500,000 patients, with annual incidence of ~120,000.
  • The presentation noted that there are no advanced small molecule oral medications approved for EoE.

Financial Impact

No financial data or guidance provided; the filing is a pipeline update with preclinical and early clinical data.

Risk Factors

  • All data presented is preclinical or Phase 1; clinical efficacy and safety in EoE are unproven.
  • The company has a small market cap ($69M) and may require additional capital to fund development.
  • Competition from approved biologics (dupilumab) and other JAK inhibitors in development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-455669
Document: acrv-ex99_1.htm0001193125-26-455669
Document: 0001193125-26-455669-index-headers.html0001193125-26-455669
Document: 0001193125-26-455669-index.html0001193125-26-455669
Document: 0001193125-26-455669.txt0001193125-26-455669

Track record

8 reports on ACRV

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry $1.45 Now $1.46 +0.69% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $1.57 Now $1.46 −7.01% settles Feb 9
  3. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $1.61 Now $1.46 −9.32% settles Feb 4
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $1.61 Now $1.46 −9.32% settles Feb 4
  5. Jul 21, 202616w ago Press Release Neutral 3/10 Entry $1.68 to $1.76 Now $1.46 −13.10% ▲ +4.76% +1.50% vs SPY
  6. May 22, 202625w ago DEFA14A Neutral 3/10 Entry $1.67 to $2.39 Now $1.46 −12.57% ▲ +43.11% +40.39% vs SPY
  7. Apr 30, 202628w ago DEFA14A Neutral 2/10 Entry $1.85 to $1.56 Now $1.46 −21.08% ▼ −15.68% −18.78% vs SPY
  8. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $1.70 to $1.52 Now $1.46 −14.12% ▼ −10.59% −24.93% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026